Navigation Links
TPI's Qionglai Facility (QLF) Construction Completed
Date:5/1/2013

CHENGDU, China, May 1, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided the updates on its Qionglai Facility (QLF). The construction of QLF has been completed in mid April as previously projected which was immediately followed by equipment installation and a series of procedures that prepares the plant for the final GMP certification. The Company targets mid June 2013 for the GMP certification process initiation for the QLF TCM pre-extraction facility.

The pre-extraction facility will conduct initial processing of TCM raw material, separation using alcohol or water precipitation, filtration, centrifugation, concentration and purification of TCM pharmaceutical ingredients which will be further processed for the production of mTCM at the formulation facility.

About Pre-extraction and formulation plant development at QLF

In preparation for the new GMP standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities in compliance with the new GMP standards. Due to the redesigning of the industrial parks in the suburbs of Chengdu, TPI's manufacturing facility at the Longquan district, east of Chengdu, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for pharmaceutical industry. The QLF is approximately 18 miles from the Company's recently completed Jiangchuan macrolide (JCM) facility. The proposed relocation project also includes our TCM pre-extraction plant which is located near the center of Chengdu surrounded by rapidly expanding residential area. The QLF is estimated to be 80 mu or 53,000 square meters. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at TPI's facilities.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tpi.asia

Tel: +86-28-8551-6696 (Chengdu, China)
      +86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza     
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TPI Targets Qionglai Facility (QLF) Construction Completion in Mid April
2. TPI Provides Progress Update on Qionglai Facility (QLF) Construction
3. Horizon Technology Finance Closes $2 Million Venture Loan Facility with New Haven Pharmaceuticals
4. GE alliance awarded contract to design new plant-based manufacturing facility in Brazil
5. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
6. Novum to Open State-of-the-Art Clinical Research Facility in Houston, TX
7. Compass Diversified Holdings Expands Term Loan Facility by $30 Million and Lowers Interest Rate by 1.25%
8. Cellular Dynamics International Opens Facility in California, Leasing Space from the Buck Institute to Derive and Bank Human Induced Pluripotent Stem Cells
9. Texas A&M System and GlaxoSmithKline receive U.S. Government approval to establish influenza vaccine facility in Texas
10. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
11. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” ... Water, Global Climate Change and Your Health on Voice America sponsored by Nature’s ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management Association ... for 2017-2018. The annual board election process has been in place since the RBMA ... Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. ... board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
Breaking Medicine News(10 mins):